|
| Press Releases |
|
 |
|
| Tuesday, November 17, 2015 |
|
|
Successful Ruling in Patent Infringement Litigation for Antiemetic Agent Aloxi in the United States |
Eisai Co., Ltd. announced today that the U.S. District Court for the District of New Jersey has ruled in favor of Helsinn Healthcare S.A. in the patent infringement lawsuit for antiemetic agent ALOXI (palonosetron hydrochloride) brought by Helsinn together with Roche Palo Alto LLC (Roche) against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. in the United States, where it was determined that certain formulation patent claims for ALOXI are valid and infringed.
more info >> |
|
| Thursday, November 5, 2015 |
|
|
Eisai to Commence Two Joint Research Programs toward Development of New Antimalarial Medicines |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has entered into two joint research agreements for the development of new antimalarial medicines. more info >> |
|
| Monday, November 2, 2015 |
|
|
Eisai Presents Results from Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan Oral Presentation Given at 49th Congress of The Japan Epilepsy Society |
| Eisai Co., Ltd. announced today that an oral presentation highlighting results from a Phase III clinical study (Study 335) of its in-house developed antiepileptic drug (AED) perampanel hydrate (global product name: Fycompa) in patients with refractory partial-onset seizures conducted in Asia, including Japan, was given at the 49th Congress of the Japan Epilepsy Society held from October 30 to 31 in Nagasaki, Japan. more info >> |
|
| Monday, October 19, 2015 |
|
|
Phase II Trial Results on Novel Anticancer Agent Lenvima in Renal Cell Carcinoma Published in the Lancet Oncology |
| Eisai Co., Ltd. announced today that the results of a Phase II clinical trial (Study 205) of its in-house developed novel anticancer agent Lenvima in advanced or metastatic renal cell carcinoma have been published in the online version of The Lancet Oncology, a leading clinical oncology research journal that is highly regarded worldwide. more info >> |
|
| Monday, October 5, 2015 |
|
|
Eisai to Provide Diethylcarbamazine Citrate Tablets Free of Charge for Use in National Lymphatic Filariasis Elimination Campaign in Indonesia |
| Eisai Co., Ltd. announced today that it has provided 151 million 100 mg tablets of the lymphatic filariasis treatment diethylcarbamazine citrate (DEC) free of charge for use in mass drug administration (MDA) conducted through the BELKAGA campaign being promoted by the Government of Indonesia. more info >> |
|
| Tuesday, September 29, 2015 |
|
|
U.S. FDA Grants Priority Review Status to sNDA for Anticancer Agent Halaven as Treatment for Soft Tissue Sarcoma |
| Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Eisai's in-house developed anticancer agent Halaven (eribulin mesylate) as a treatment for soft tissue sarcoma, and granted the sNDA Priority Review status. more info >> |
|
|
Eisai Receives Additional Approval in Japan for Vascular Embolization Device DC Bead as Treatment of Hypervascular Tumors and Arteriovenous Malformations |
| Eisai Co., Ltd. announced today that it has received additional approval for the vascular embolization device DC Bead to be used for the treatment of hypervascular tumors and arteriovenous malformations (AVM) in Japan. more info >> |
|
| Friday, September 25, 2015 |
|
|
Eisai to Sponsor Lectures at Japan Research Center of Fudan University in China |
| Eisai Co., Ltd announced today that its holding company in China, Eisai China Holdings Ltd., will sponsor lectures at the Japan Research Center of Fudan University, one of China's top academic institutes, in Shanghai. more info >> |
|
| Monday, September 14, 2015 |
|
|
Eisai to Present Latest Clinical Data on Lenvima (Lenvatinib) and Halaven (Eribulin) at European Cancer Congress |
Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Lenvima and Halaven will be presented during the European Cancer Congress (ECC) 2015, taking place in Vienna, Austria, from September 25 to 29.
more info >> |
|
| Thursday, September 10, 2015 |
|
|
Drugs for Neglected Diseases initiative and Eisai to Test Drug Candidate for Eumycetoma Patients suffering from virtually no R&D for this neglected disease |
| The Drugs for Neglected Diseases initiative (DNDi) and the Japanese pharmaceutical company Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai's anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 20:42 HKT/SGT
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities 
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
|
|
|
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
Nov 21, 2024 21:29 HKT/SGT
|
|
|
neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Nov 21, 2024 21:20 HKT/SGT
|
|
|
Experience the Power of Movement: Jin Pilates Brings Singapore's First Garuda Studio for Dynamic, Holistic Wellness
Nov 21, 2024 20:19 HKT/SGT
|
|
|
SGX-Listed Mooreast Appoints Norwegian Eirik Ellingsen as CEO to Drive Growth in Global Floating Offshore Wind Market
Nov 21, 2024 19:00 HKT/SGT
|
|
|
DesignInspire opens on December 5, with free admission for the public
Nov 21, 2024 17:54 HKT/SGT
|
|
|
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
|
|
|
Yahoo Finance Invest Asia 2024 - Disrupting Finance: Innovations Shaping The Future
Nov 21, 2024 14:14 HKT/SGT
|
|
|
TGL Presented by SoFi Names SYNLawn As Official Synthetic Surface Partner, Providing 31,000 Square Feet of Turf for SoFi Center's Tech-Infused Field of Play
Nov 21, 2024 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
